


PERFLUOROOCTANOIC ACID (PFOA) AND PERFLUOROOCTANESULFONIC ACID (PFOS)

VOLUME 135



This publication represents the views and expert opinions of an IARC Working Group on the Identification of Carcinogenic Hazards to Humans, which met in Lyon, France, 7–14 November 2023

LYON, FRANCE - 2025

IARC MONOGRAPHS
ON THE IDENTIFICATION
OF CARCINOGENIC HAZARDS
TO HUMANS

CONTENTS

NOTE TO THE READER	1
LIST OF PARTICIPANTS	3
PREAMBLE	9
A. GENERAL PRINCIPLES AND PROCEDURES	9
1. Background.....	9
2. Objective and scope.....	10
3. Selection of agents for review.....	11
4. The Working Group and other meeting participants.....	11
5. Working procedures.....	13
6. Overview of the scientific review and evaluation process.....	14
7. Responsibilities of the Working Group.....	16
B. SCIENTIFIC REVIEW AND EVALUATION	17
1. Exposure characterization.....	17
2. Studies of cancer in humans.....	20
3. Studies of cancer in experimental animals.....	25
4. Mechanistic evidence.....	28
5. Summary of data reported.....	31
6. Evaluation and rationale.....	32
References.....	37
GENERAL REMARKS	41
1. EXPOSURE CHARACTERIZATION	49
1.1 Identification of the agent.....	49
1.2 Production and uses.....	55
1.3 Detection and quantification.....	57
1.4 Occurrence and exposure.....	68
1.5 Regulations and guidelines.....	112
1.6 Quality of exposure assessment in key epidemiological studies of cancer and mechanistic studies in humans.....	116
References.....	131

2. CANCER IN HUMANS	157
2.1 Cohort descriptions	158
2.2 Cancers of the urinary tract	213
2.3 Cancers of the male genital tract	252
2.4 Cancers of the breast and thyroid gland	280
2.5 Cancers of the digestive tract	347
2.6 Cancers of the brain and lymphatic and haematopoietic tissue	358
2.7 Cancer of all sites combined	366
2.8 Evidence synthesis for cancer in humans	370
References	390
3. CANCER IN EXPERIMENTAL ANIMALS	397
3.1 Perfluorooctanoic acid (PFOA)	397
3.2 Perfluorooctanesulfonic acid (PFOS)	425
3.3 Evidence synthesis for cancer in experimental animals	435
References	438
4. MECHANISTIC EVIDENCE	441
4.1 Absorption, distribution, metabolism, and excretion	441
4.2 Evidence relevant to key characteristics of carcinogens	454
4.3 Evaluation of high-throughput in vitro screening data	658
References	662
5. SUMMARY OF DATA REPORTED	705
5.1 Exposure characterization	705
5.2 Cancer in humans	706
5.3 Cancer in experimental animals	710
5.4 Mechanistic evidence	711
6. EVALUATION AND RATIONALE	717
6.1 Cancer in humans	717
6.2 Cancer in experimental animals	717
6.3 Mechanistic evidence	717
6.4 Overall evaluation	717
6.5 Rationale	717
LIST OF ABBREVIATIONS	719
ANNEX 1. Supplementary material for Section 1, Exposure Characterization	727
ANNEX 2. Actions and regulations for the elimination of PFAS worldwide	729
ANNEX 3. Supplementary analyses used in reviewing evidence on cancer in humans	733
ANNEX 4. Supplementary material for Section 2, Cancer in Humans	747
ANNEX 5. Supplementary material for Sections 4.1 and 4.2, Mechanistic Evidence	749

ANNEX 6. Supplementary material for Section 4.3, Mechanistic Evidence751

SUMMARY OF FINAL EVALUATIONS.....753